Caribou Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CRBU | CRSP | CLLS | DTIL | RNAC | BOLD | |
|---|---|---|---|---|---|---|
| Market cap | 47.64M | 5.02B | 117.86M | 226.84M | 206.34M | 55.65M |
| P/E (TTM) | — | — | — | 32.5 | — | — |
| Forward P/E | -0.5 | -14.4 | -1.9 | -4.4 | -1.8 | -2.4 |
| Price/book | 0.5 | 3.0 | 2.1 | 4.4 | -1.6 | 0.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −79.25% | −8.54% | −62.62% | +26.09% | −16.43% | +90.48% |
| Today | −3.27% | +3.57% | +7.34% | +16.50% | +6.40% | +0.84% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CRBU news ›Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology Annual Meeting
Investing News Network Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology Annual Meeting Caribou Biosciences, Inc. (Nasdaq: CRBU) today announced that vispa-cel
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biop... Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor…
Caribou Biosciences (CRBU) Gets a Buy from Citi
Citi analyst Yigal Nochomovitz maintained a Buy rating on Caribou Biosciences on May 8 and set a price target of $8.00. The company’s shares closed last Friday at $1.94. According to TipRanks, Nochomovitz is a 4-star analyst with an…
Bank of America Securities Remains a Buy on Caribou Biosciences (CRBU)
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Caribou Biosciences yesterday and set a price target of $6.00. The company’s shares closed yesterday at $2.03. Stranahan covers the Healthcare sector, focusing on…
Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock Now Rated “Hold” by Sell-Side Brokerages
Posted by Tristan Rich on Oct 21st, 2026 Read Our Latest Report on Caribou Biosciences Shares of NASDAQ:CRBU opened at $0.52 on Wednesday. The company has a market cap of $55.64 million, a price-to-earnings ratio of -0.48 and a beta of…
Multiple Myeloma Pipeline 2026: Who Is Leading the Race? Top Companies and Emerging Therapies to Watch by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics
Albany New York October 20 2026 As per DelveInsight s assessment globally Multiple Myeloma pipeline constitutes 75 key companies continuously working towards developing 80 Multiple Myeloma treatment therapies analysis of Clinical Trials…
Cibus (NASDAQ:CBUS) Stock Rating Lowered by Wall Street Zen
Posted by Kim Johansen on Oct 19th, 2026 Cibus (NASDAQ:CBUS – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on…
Caribou halts its allogeneic CAR T programs as funding dries up
The company cited a tough financing market for off-the-shelf cell therapies, as investment shifts toward in vivo CAR T. The decision came down to money. The company, cofounded by Nobel laureate Jennifer Doudna, said it will make…
More from 1 other outlet
StockWatch: Caribou Plunges as It Pursues Strategic Alternatives
CRISPR genome-editing cell therapy developer plunges 60% on announcement of plans to assess strategic alternatives, halt clinical trials, and cut workforce ‘substantially’ A Caribou Biosciences researcher at work. Caribou, whose…
Caribou Biosciences Halts Off-the-Shelf CRISPR CAR-T Programs for Lymphoma and Myeloma After Failing to Fund Phase 3 Trial
STAT reported on Oct. 7 that the company is shutting down. Chief executive Rachel Haurwitz told STAT that Caribou had worked out a phase 3 design with the FDA, but raising money to pay for the study proved too difficult. For patients with…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com6
- themarketsdaily.com5
- defenseworld.net4
- tradingview.com2
- allsci.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 40 articles, not a forecast.